FDA Approval marks first presentation of bivalirudin in frozen, premixed, ready-to-use formulation | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Feeds:: Posts; Comments

« What Level of Blood Pressure (BP) should be Treated? Comments on the New Guidelines

Employment Trends in Biomedical – NIH Visualization Tool of Job Segmentation for Life Scientists »

FDA Approval marks first presentation of bivalirudin in frozen, premixed, ready-to-use formulation

January 24, 2018 by 2012pharmaceutical

FDA Approval marks first presentation of bivalirudin in frozen, premixed, ready-to-use formulation

Reporter: Aviva Lev-Ari, PhD, RN

Baxter Announces FDA Approval of Ready-to-Use Cardiovascular Medication Bivalirudin

Approval marks first presentation of bivalirudin in frozen, premixed, ready-to-use formulation

https://www.dicardiology.com/product/baxter-announces-fda-approval-ready-use-cardiovascular-medication-bivalirudin?eid=333021707&bid=1983307

Dosing and Uses

https://reference.medscape.com/drug/angiomax-angiox-bivalirudin-342137

Posted in Cardiac and Cardiovascular Surgical Procedures, Coagulation Therapy and Internal Bleeding, PCI, Peripheral Arterial Disease & Peripheral Vascular Surgery | Leave a Comment

Leave a Reply Cancel reply

Follow Blog via Email

Enter your email address to follow this blog and receive notifications of new posts by email.

Email Address

Join 9,308 other subscribers
Recent Posts
Archives
Archives
Categories
Categories
Meta

%d bloggers like this: